VIDEO: Amivantamab plus lazertinib improved PFS vs. osimertinib in EGFR-mutated NSCLC

Press/Media

Period	Dec 1 2023

Media coverage

Title	VIDEO: Amivantamab plus lazertinib improved PFS vs. osimertinib in EGFR-mutated NSCLC
Media name/outlet	Healio
Country/Territory	United States
Date	12/1/23
URL	https://www.healio.com/news/hematology-oncology/20231201/video-amivantamab-plus-lazertinib-improved-pfs-vs-osimertinib-in-egfrmutated-nsclc
Persons	Hossein Borghaei